Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) is a pioneering clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. Agenus is steadfast in its mission to develop innovative immunological therapies aimed at leveraging the body's immune system to combat cancer and other diseases. The company’s diverse product pipeline includes immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc., and vaccine adjuvants through its subsidiary SaponiQx Inc. These products are bolstered by in-house capabilities such as current good manufacturing practice (cGMP) manufacturing and a clinical operations platform.
Agenus has developed several key product candidates, including botensilimab (AGEN1811), a next-generation Fc-engineered CTLA-4 antibody, and balstilimab, a PD-1 antibody. They are currently under investigation for their potential to treat various cancers, particularly difficult-to-treat solid tumors.
The company has achieved significant milestones, including the initiation of various clinical trials for botensilimab and balstilimab. Notably, in April 2024, Agenus announced a one-for-twenty reverse stock split of its issued and outstanding common stock to increase its stock price and meet Nasdaq Capital Market listing requirements. This move is part of a strategic plan to enhance future financing and qualify for inclusion in the Russell Indices.
In its ongoing pursuit of innovative cancer treatments, Agenus recently announced Phase 1 trial results demonstrating encouraging survival rates in patients with metastatic colorectal cancer. The Phase 2 data is expected to be submitted to a major medical conference in the latter half of 2024.
Agenus also engages in strategic partnerships to accelerate its development programs. For instance, a recent agreement with Ligand Pharmaceuticals secures a $100 million capital infusion, specifically aimed at supporting the clinical development and launch readiness of the BOT/BAL combination therapy.
The team at Agenus comprises scientists, researchers, biotechnologists, physicians, and business professionals united by the shared goal of achieving breakthroughs in cancer treatment. This collaborative spirit ensures that Agenus remains at the forefront of transformative cancer therapies, aiming to enhance patient outcomes and extend lives.
For more information, visit www.agenusbio.com or follow @agenus_bio on social media.
Agenus will release its second quarter 2022 financial results before the market opens on August 9, 2022.
The company will host a conference call at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can access the conference via the provided dial-in numbers or through a webcast.
Agenus is focused on developing therapies for cancer and infections, leveraging a diverse portfolio of therapeutic approaches.
Agenus (NASDAQ: AGEN) announces Dr. Steven O’Day's participation in a panel discussion on immuno-oncology at William Blair’s Biotech Focus Conference on July 12, 2022, at 4:10 PM EST. The conference will be held from July 12-13, 2022, at The St. Regis New York hotel, where Agenus will also conduct one-on-one investor meetings. Agenus focuses on developing therapies that harness the body's immune system to combat cancer and infections, aiming to expand patient access to cancer immunotherapy through innovative combinations and advanced manufacturing capabilities.
Agenus (NASDAQ: AGEN) has reported promising results from its Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer (MSS CRC). Key findings include a 24% overall response rate and a 73% disease control rate, with 80% of responses ongoing at data cutoff. The combination therapy has shown durability, especially in heavily pre-treated patients. A global Phase 2 study is set to begin this year, building on the strong therapeutic potential demonstrated in cold tumors.
Agenus (NASDAQ: AGEN) announced it will host a hybrid webcast on June 29, 2022, at 10:00 AM EST to discuss botensilimab/balstilimab combination data in microsatellite stable colorectal cancer (MSS-CRC). This data was presented earlier at the ESMO World Congress in Barcelona. The webcast features speakers including Steven O’Day, M.D., and Dr. Anthony El-Khoueiry, among others. Interested attendees can register through the Investors section of the Agenus website. An archived version will be available post-event.
Agenus (NASDAQ: AGEN) announces that their partner GSK's RSV vaccine candidate has shown significant efficacy in adults aged 60 and older in the AReSVi 006 phase III trial. The primary endpoint was met with no safety concerns. Anticipated global regulatory submissions are set for H2 2022. This vaccine contains QS-21 STIMULON, an adjuvant noted for its effectiveness in vaccines like Shingrix. Additionally, Agenus subsidiary SaponiQx is developing eco-friendly manufacturing processes for QS-21 STIMULON, aiming to support broad vaccine production, including responses to pandemics.
Agenus Inc. (NASDAQ: AGEN) has announced three new clinical collaborations, doubling its partnerships in immuno-oncology. Collaborations involve Targovax, Oxford BioTherapeutics, and Immunogenesis, targeting various cancers with a focus on optimizing immunotherapy combinations. The trials will explore synergistic effects of Agenus' candidates like botensilimab and balstilimab alongside other agents. This strategy aims to enhance treatment efficacy for patients with treatment-resistant solid tumors, leveraging Agenus' manufacturing and scientific capabilities.
Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, announced that Dr. Garo Armen and Dr. Steven O’Day will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:30 AM EST. The event will take place at the New York Marriott Marquis from June 8-10. One-on-one meetings with investors will also be available. A webcast of the chat can be accessed for 90 days post-event. Agenus focuses on therapies that engage the immune system to combat cancer and infections.
Agenus (NASDAQ: AGEN) has announced its Annual Shareholders Meeting set for June 8, 2022, at 3:30 p.m. ET, to be held virtually. Shareholders can register from 3:15 p.m. ET via a control number found in proxy materials. The meeting will be accessible in listen-only mode for non-shareholders. Agenus focuses on immuno-oncology, developing therapies that engage the immune system against cancer and infections, utilizing a range of advanced platforms and facilities.
Agenus Inc. (NASDAQ: AGEN) announces botensilimab's late-breaking presentation at the ESMO World Congress on Gastrointestinal Cancer, focusing on treating heavily pretreated MSS colorectal cancer. The company also reveals a strategic plan to cut operating costs by 20% in 2022. Positive clinical responses were highlighted, with botensilimab and balstilimab showing efficacy in difficult-to-treat patients. Agenus aims to accelerate development and prioritize high-potential programs while enhancing operational efficiencies through advanced technologies.
Agenus Inc. (NASDAQ: AGEN) announced significant clinical advancements in its immuno-oncology pipeline. The company is set to initiate Phase 2 trials for botensilimab targeting colorectal, melanoma, and pancreatic cancers, with data updates expected in Q3. AGEN1571 trials will commence following its presentation at AACR, while AGEN2373 is progressing, evidenced by a $5 million milestone payment from Gilead, with potential future payments up to $570 million. Financially, Agenus reported $26 million in revenue for Q1 2022, an increase of $14 million year-over-year, and a net loss of $51 million.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
What does Agenus Inc. specialize in?
Where is Agenus Inc. headquartered?
What are the key products of Agenus Inc.?
What recent strategic financial move did Agenus make?
What significant agreement did Agenus secure recently?
What are some recent clinical trial achievements of Agenus?
What is the focus of Agenus' product candidates?
Who are part of the Agenus team?
How does Agenus support its product development?
Where can investors find more information about Agenus?
